- Home
- AMLX vs DAWN Comparison
AMLX vs DAWN Comparison
Compare AMLX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | DAWN |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMLX | DAWN |
|---|---|---|
| Price | $15.72 | $11.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $17.43 | ★ $27.56 |
| AVG Volume (30 Days) | 1.8M | ★ 2.7M |
| Earning Date | 03-03-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $133,672,000.00 |
| Revenue This Year | N/A | $17.32 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.11 |
| 52 Week Low | $2.60 | $5.64 |
| 52 Week High | $17.49 | $13.53 |
Technical Indicators
Market Signals| Indicator | AMLX | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 63.83 |
| Support Level | $12.08 | $9.84 |
| Resistance Level | $17.49 | $13.20 |
| Average True Range (ATR) | 1.01 | 0.98 |
| MACD | 0.50 | 0.24 |
| Stochastic Oscillator | 73.42 | 74.74 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.